A new trading day began on Monday, with Unity Biotechnology Inc (NASDAQ: UBX) stock price down -50.21% from the previous day of trading, before settling in for the closing price of $0.77. UBX’s price has ranged from $0.66 to $3.10 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 39.36%. Meanwhile, its annual earnings per share averaged 42.21%. With a float of $15.68 million, this company’s outstanding shares have now reached $17.21 million.
Considering the fact that the conglomerate employs 16 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Unity Biotechnology Inc (UBX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Unity Biotechnology Inc is 8.92%, while institutional ownership is 11.46%. The most recent insider transaction that took place on Apr 02 ’25, was worth 18,388. In this transaction CLO and Head of Ops of this company sold 17,852 shares at a rate of $1.03, taking the stock ownership to the 48,753 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Officer proposed sale 17,852 for $1.03, making the entire transaction worth $18,305.
Unity Biotechnology Inc (UBX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 42.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.77% during the next five years compared to 39.36% growth over the previous five years of trading.
Unity Biotechnology Inc (NASDAQ: UBX) Trading Performance Indicators
Here are Unity Biotechnology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.95.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.63, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Unity Biotechnology Inc (UBX)
Compared to the last year’s volume of 0.3 million, its volume of 0.52 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 20.15%.
During the past 100 days, Unity Biotechnology Inc’s (UBX) raw stochastic average was set at 1.40%, which indicates a significant decrease from 3.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 301.14% in the past 14 days, which was higher than the 146.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8324, while its 200-day Moving Average is $1.3053. Nevertheless, the first resistance level for the watch stands at $0.6175 in the near term. At $0.8510, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.9819. If the price goes on to break the first support level at $0.2531, it is likely to go to the next support level at $0.1222.
Unity Biotechnology Inc (NASDAQ: UBX) Key Stats
With a market capitalization of 6.61 million, the company has a total of 17,212K Shares Outstanding. Currently, annual sales are 0 K while annual income is -25,990 K. The company’s previous quarter sales were 0 K while its latest quarter income was -7,300 K.
